Supplementary figures - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

figure

posted on 2022-04-29, 08:29 authored by Ninad Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E. Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda

Supplemental figure 1. HRs of OS for ide-cel versus conventional care based on the triple- or quad-refractory population from MAMMOTH.

Supplemental figure 2. HRs of OS for ide-cel versus conventional care based on the penta-refactory population from MAMMOTH.

History

Usage metrics

Keywords

CAR T cell therapy conventional care idecabtagene vicleucel matching-adjusted indirect comparison outcomes research relapsed and refractory multiple myeloma triple-class exposed

Licence

CC BY-NC-ND 4.0

Supplementary figures - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

History

Usage metrics

Categories

Keywords

Licence

Exports